FDA Panel To Review Edwards’ Sapien
The Advisory Panel of the US Food and Drug Administration (‘FDA’) will review Edwards Lifesciences’ (NYSE:EW) Sapien transcatheter heart valve (‘THV’) on June 13, 2012. The Panel will review the device for the treatment of patients with severe, symptomatic aortic stenosis who are at high risk of surgery (Cohort A). Sapien had received FDA approval [...]
The Advisory Panel of the US Food and Drug Administration (‘FDA’) will review Edwards Lifesciences’ (NYSE:EW) Sapien transcatheter heart valve (‘THV’) on June 13, 2012. The Panel will review the device for the treatment of patients with severe, symptomatic aortic stenosis who are at high risk of surgery (Cohort A). Sapien had received FDA approval for the treatment of certain inoperable patients in November last year.
Last month, Edwards presented positive long-term data from Cohort A of … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards